The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis

Journal of Affective Disorders
Joshua D RosenblatRoger S McIntyre

Abstract

Pharmacogenomic testing has recently become scalable and available to guide the treatment of major depressive disorder (MDD). The objective of the current meta-analysis was to determine if guidance from pharmacogenomic testing results in relatively higher rates of remission and response compared to treatment as usual (i.e., 'unguided' trial-and-error method) in adults with MDD. Article databases were systematically searched from inception to December 2, 2017 for human studies assessing the clinical utility of pharmacogenomics in the acute treatment of MDD. Treatment outcomes in MDD may be defined continuously or categorically (i.e., response/remission). Herein, we delimit our focus on categorical outcomes. Using a random-effects model, data was pooled to determine the risk ratio (RR) of response and remission, respectively, in the pharmacogenomic-guided treatment group compared to the unguided group. Four randomized controlled trials (RCTs) and two open-label, controlled cohort studies were included. The pooled RR for treatment response comparing guided versus unguided treatment was 1.36 (95% confidence interval [CI] = 1.14 to 1.62; p = 0.0006; n = 799) in favour of guided treatment. The pooled RR for remission was 1.74 (95%CI ...Continue Reading

Citations

Mar 28, 2019·Expert Review of Clinical Pharmacology·Ramón CacabelosJuan C Carril
Feb 18, 2020·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Abdullah Al MarufChad A Bousman
Jul 16, 2020·Depression and Anxiety·Michael J McCarthyJohn R Kelsoe
Jul 10, 2019·Frontiers in Psychiatry·Joseph P JarvisJeffrey A Shaman
May 8, 2020·Current Psychiatry Reports·Lisa B NamerowSalma Malik
Aug 21, 2020·Nature Reviews. Disease Primers·Stefan M GoldChristian Otte
Apr 30, 2020·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Erika L Nurmi
Feb 23, 2019·Frontiers in Neuroscience·Hope PanAna M D Carneiro
Nov 5, 2020·Pharmacopsychiatry·Chad A BousmanDaniel J Müller
Sep 29, 2019·Journal of Psychiatric Research·Julia TomasiArun K Tiwari
Nov 11, 2019·The Nursing Clinics of North America·Kathleen T McCoyLinda Sue Hammonds
Jan 29, 2021·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kyung Ho LeeChi-Un Pae
Mar 7, 2021·Journal of Personalized Medicine·Angelos HalarisElizabeth A Whitham
May 29, 2021·Schizophrenia Research·Amanda J LisowayJames L Kennedy
Jun 3, 2021·Journal of Personalized Medicine·Benjamin LaplaceEric Charles
Aug 28, 2021·International Journal of Environmental Research and Public Health·Carl B RothChristian G Huber
Oct 8, 2021·Translational Psychiatry·Catherine R VirelliJames L Kennedy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.